Role of clinical biomarkers in predicting the effectiveness of omalizumab.
Qing ZhangChunxiao LiJingxuan WanMengyuan ZhangYing NongJiang-Tao LinPublished in: Therapeutic advances in respiratory disease (2023)
The responsiveness of omalizumab is not associated with pretreatment clinical biomarkers, and these biomarkers should not be used to predict the responsiveness of omalizumab.